Drug evaluation: TAK-475 - an oral inhibitor of squalene synthase for hyperlipidemia

被引：0

作者：

Burnett, John R. ^{[1
]}

机构：

[1] Royal Perth Hosp, PathW Lab Med WA, Dept Core Clin Pathol & Biochem, Perth, WA 6847, Australia

来源：

CURRENT OPINION IN INVESTIGATIONAL DRUGS | 2006年 / 7卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Takeda Pharmaceutical Co Ltd is developing TAK-475, a squalene synthetase inhibitor from a series of 4,1-benzoxazepine-3-acetic acid derivatives, for the potential oral treatment of hyperlipidemia. By March 2005, TAK-475 was undergoing phase III clinical trials in the US and Europe.

引用

页码：850 / 856

页数：7

共 40 条

[1] Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia [J].

Amano, Y ;

Nishimoto, T ;

Tozawa, R ;

Ishikawa, E ;

Imura, Y ;

Sugiyama, Y .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 466 (1-2) :155-161

[2] Rationale for combination therapy with statin drugs in the treatment of dyslipidemia [J].

Ansell B.J. .

Current Atherosclerosis Reports, 2005, 7 (1) :29-33

[3] Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction [J].

Ballantyne, CM .

AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (9A) :14K-19K

[4]

Bostedor RG, 1997, J BIOL CHEM, V272, P9197

[5]

DAVIGNON J, 1992, CAN J CARDIOL, V8, P843

[6] Orally active squalene synthase inhibitors: Bis((acyloxy)alkyl) prodrugs of the alpha-phosphonosulfonic acid moiety [J].

Dickson, JK ;

Biller, SA ;

Magnin, DR ;

Petrillo, EW ;

Hillyer, JW ;

Hsieh, DC ;

Lan, SJ ;

Rinehart, JK ;

Gregg, RE ;

Harrity, TW ;

Jolibois, KG ;

Kalinowski, SS ;

Kunselman, LK ;

Mookhtiar, KA ;

Ciosek, CP .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) :661-664

[7] Sterols and isoprenoids: Signaling molecules derived from the cholesterol biosynthetic pathway [J].

Edwards, PA ;

Ericsson, J .

ANNUAL REVIEW OF BIOCHEMISTRY, 1999, 68 :157-185

[8] Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro [J].

Flint, OP ;

Masters, BA ;

Gregg, RE ;

Durham, SK .

TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 145 (01) :91-98

[9] REGULATION OF THE MEVALONATE PATHWAY [J].

GOLDSTEIN, JL ;

BROWN, MS .

NATURE, 1990, 343 (6257) :425-430

[10] Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [J].

Grundy, SM ;

Cleeman, JI ;

Merz, CNB ;

Brewer, HB ;

Clark, LT ;

Hunninghake, DB ;

Pasternak, RC ;

Smith, SC ;

Stone, NJ .

CIRCULATION, 2004, 110 (02) :227-239

← 1 2 3 4 →